Astellas Pharma US, Inc.

Astellas Pharma US, Inc.
1 Astellas Way
Northbrook, IL 60062
(800) 888-7704Website: https://www.astellas.com/us/Careers: https://astellascareers.jobsPatient Assistance Program: https://www.astellas.com/us/patients-and-caregivers

Latest News

U.S. Food and Drug Administration Expands Indication for Prograf for Prevention of Organ Rejection in Adult and Pediatric Lung Transplant Recipients - July 20, 2021
U.S. FDA Grants Regular Approval and Expands Indication for Padcev (enfortumab vedotin-ejfv) for Patients with Locally Advanced or Metastatic Urothelial Cancer - July 9, 2021
FDA Approves VESIcare LS (solifenacin succinate) Oral Suspension for Neurogenic Detrusor Overactivity (NDO) Pediatric Patients - May 27, 2020
FDA Approves Expanded Indication of Mycamine (micafungin for injection) for the Treatment of Invasive Candidiasis in Pediatric Patients Less Than 4 Months of Age - January 8, 2020
FDA Approves Padcev (enfortumab vedotin-ejfv) for Locally Advanced or Metastatic Urothelial Cancer, the Most Common Type of Bladder Cancer - December 18, 2019
FDA Approves Xtandi (enzalutamide) for the Treatment of Metastatic Castration-Sensitive Prostate Cancer (mCSPC) - December 16, 2019
Seattle Genetics and Astellas Announce Results from Phase 1 Trial of Investigational Agent Enfortumab Vedotin in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Bladder Cancer - September 28, 2019
Astellas and Seattle Genetics Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer - July 16, 2019
Astellas and Seattle Genetics Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer - June 3, 2019
Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer - March 28, 2019

Drugs Associated with Astellas Pharma US, Inc.

Astellas Pharma US, Inc. manufactures, markets and/or distributes more than 13 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.

Brand/Generic Name	Reviews	Rating
AmBisome Generic name: amphotericin b liposomal Drug class: polyenes
Astagraf XL Generic name: tacrolimus Drug class: calcineurin inhibitors
Cresemba Generic name: isavuconazonium Drug class: azole antifungals
Lexiscan Generic name: regadenoson Drug class: cardiac stressing agents	26 reviews	5.0 / 10
Mycamine Generic name: micafungin Drug class: echinocandins
Myrbetriq Generic name: mirabegron Drug class: urinary antispasmodics	218 reviews	4.8 / 10
Padcev Generic name: enfortumab vedotin Drug class: miscellaneous antineoplastics	2 reviews	1.0 / 10
Prograf Generic name: tacrolimus Drug class: calcineurin inhibitors	24 reviews	8.0 / 10
Tarceva Generic name: erlotinib Drug class: EGFR inhibitors	35 reviews	8.4 / 10
VESIcare Generic name: solifenacin Drug class: urinary antispasmodics	129 reviews	5.6 / 10
VESIcare LS Generic name: solifenacin Drug class: urinary antispasmodics
Xospata Generic name: gilteritinib Drug class: multikinase inhibitors	1 review	8.0 / 10
Xtandi Generic name: enzalutamide Drug class: antiandrogens, hormones/antineoplastics	13 reviews	5.4 / 10
For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective).